Aberrant promoter methylation of the cadherin 13 gene in serum and its relationship with clinicopathological features of prostate cancer

Wang, Li; Lin, Ying‐Li; Li, Bo; Wang, Yu‐Zhong; Ma, Jun

doi:10.1177/0300060514540631

Cited by 24 publications

(20 citation statements)

References 24 publications

(47 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It has been shown that protocadherins behave as tumor suppressor genes in many solid cancers such as non-small-cell lung cancer, gastric and prostate cancer. It has also been demonstrated that their involvement is due to aberrant DNA methylation that determines an altered expression pattern [36–38]. …”

Section: Discussionmentioning

confidence: 99%

Global DNA methylation profiling uncovers distinct methylation patterns of protocadherin alpha4 in metastatic and non-metastatic rhabdomyosarcoma

et al. 2016

View full text Add to dashboard Cite

BackgroundRhabdomyosarcoma (RMS), which can be classified as embryonal RMS (ERMS) and alveolar RMS (ARMS), represents the most frequent soft tissue sarcoma in the pediatric population; the latter shows greater aggressiveness and metastatic potential with respect to the former. Epigenetic alterations in cancer include DNA methylation changes and histone modifications that influence overall gene expression patterns. Different tumor subtypes are characterized by distinct methylation signatures that could facilitate early disease detection and greater prognostic accuracy.MethodsA genome-wide approach was used to examine methylation patterns associated with different prognoses, and DNA methylome analysis was carried out using the Agilent Human DNA Methylation platform. The results were validated using bisulfite sequencing and 5-aza-2′deoxycytidine treatment in RMS cell lines. Some in vitro functional studies were also performed to explore the involvement of a target gene in RMS tumor cells.ResultsIn accordance with the Intergroup Rhabdomyosarcoma Study (IRS) grouping, study results showed that distinct methylation patterns distinguish RMS subgroups and that a cluster of protocadherin genes are hypermethylated in metastatic RMS. Among these, PCDHA4, whose expression was decreased by DNA methylation, emerged as a down-regulated gene in the metastatic samples. As PCDHA4-silenced cells have a significantly higher cell proliferation rate paralleled by higher cell invasiveness, PCDHA4 seems to behave as a tumor suppressor in metastatic RMS.ConclusionStudy results demonstrated that DNA methylation patterns distinguish between metastatic and non-metastatic RMS and suggest that epigenetic regulation of specific genes could represent a novel therapeutic target that could enhance the efficiency of RMS treatments.Electronic supplementary materialThe online version of this article (doi:10.1186/s12885-016-2936-3) contains supplementary material, which is available to authorized users.

show abstract

Section: Discussionmentioning

confidence: 99%

Global DNA methylation profiling uncovers distinct methylation patterns of protocadherin alpha4 in metastatic and non-metastatic rhabdomyosarcoma

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Moreover, individually, serum PCDH17 me , PCDC10 me and PCDH8 me were also associated with advanced clinical stage, higher preoperative serum PSA, as well as lymph node metastasis and shorter biochemical recurrence-free survival [193][194][195]. Besides being also associated with Gleason score, advanced tumor stage and high PSA, CDH13 me was further associated with shorter OS [183].…”

Section: Prognosis Predicition and Monitoringmentioning

confidence: 91%

DNA Methylation-Based Testing in Liquid Biopsies as Detection and Prognostic Biomarkers for the Four Major Cancer Types

Constâncio

Nunes

Henrique

et al. 2020

Cells

132

117

View full text Add to dashboard Cite

Lung, breast, colorectal, and prostate cancers are the most incident worldwide. Optimal population-based cancer screening methods remain an unmet need, since cancer detection at early stages increases the prospects of successful and curative treatment, leading to a lower incidence of recurrences. Moreover, the current parameters for cancer patients’ stratification have been associated with divergent outcomes. Therefore, new biomarkers that could aid in cancer detection and prognosis, preferably detected by minimally invasive methods are of major importance. Aberrant DNA methylation is an early event in cancer development and may be detected in circulating cell-free DNA (ccfDNA), constituting a valuable cancer biomarker. Furthermore, DNA methylation is a stable alteration that can be easily and rapidly quantified by methylation-specific PCR methods. Thus, the main goal of this review is to provide an overview of the most important studies that report methylation biomarkers for the detection and prognosis of the four major cancers after a critical analysis of the available literature. DNA methylation-based biomarkers show promise for cancer detection and management, with some studies describing a “PanCancer” detection approach for the simultaneous detection of several cancer types. Nonetheless, DNA methylation biomarkers still lack large-scale validation, precluding implementation in clinical practice.

show abstract

“…DNA was extracted from 0.8 ml archived serum from each patient using the QIAmp DNA Blood Mini Kit (Qiagen, Valencia, CA, USA), according to the manufacturer’s instructions. The isolated DNA was modified with bisulfite using the EpiTect Bisulfite Kit (Qiagen, Valencia, CA, USA) and standard protocol as described previously [ 27 , 28 ]. The methylation status of PCDH10 was detected using MSP, as previously described [ 24 , 28 ].…”

Section: Methodsmentioning

confidence: 99%

Prognostic Value of Protocadherin10 (PCDH10) Methylation in Serum of Prostate Cancer Patients

et al. 2016

Self Cite

View full text Add to dashboard Cite

BackgroundProstate cancer is a heterogeneous malignancy with outcome difficult to predict. Currently, there is an urgent need to identify novel biomarkers that can accurately predict patient outcome and improve the treatment strategy. The aim of this study was to investigate the methylation status of PCDH10 in serum of prostate cancer patients and its potential relevance to clinicopathological features and prognosis.Material/MethodsThe methylation status of PCDH10 in serum of 171 primary prostate cancer patients and 65 controls was evaluated by methylation-specific PCR (MSP), after which the relationship between PCDH10 methylation and clinicopathologic features was evaluated. Kaplan-Meier survival analysis and Cox analysis were used to evaluate the correlation between PCDH10 methylation and prognosis.ResultsPCDH10 methylation occurred frequently in serum of prostate cancer patients. Moreover, PCDH10 methylation was significantly associated with higher preoperative PSA level, advanced clinical stage, higher Gleason score, lymph node metastasis, and biochemical recurrence (BCR). In addition, patients with methylated PCDH10 had shorter BCR-free survival and overall survival than patients with unmethylated PCDH10. Univariate and multivariate Cox proportional hazards model analysis indicated that PCDH10 methylation in serum is an independent predictor of worse BCR-free survival and overall survival.ConclusionsPCDH10 methylation in serum is a potential prognostic biomarker for prostate cancer.

show abstract

Aberrant promoter methylation of the cadherin 13 gene in serum and its relationship with clinicopathological features of prostate cancer

Cited by 24 publications

References 24 publications

Global DNA methylation profiling uncovers distinct methylation patterns of protocadherin alpha4 in metastatic and non-metastatic rhabdomyosarcoma

Global DNA methylation profiling uncovers distinct methylation patterns of protocadherin alpha4 in metastatic and non-metastatic rhabdomyosarcoma

DNA Methylation-Based Testing in Liquid Biopsies as Detection and Prognostic Biomarkers for the Four Major Cancer Types

Prognostic Value of Protocadherin10 (PCDH10) Methylation in Serum of Prostate Cancer Patients

Contact Info

Product

Resources

About